Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

Talarico, Rosaria;Italiano, Nazzareno;Emmi, Giacomo;Piga, Matteo;Cantarini, Luca;Mattioli, Irene;Floris, Alberto;Gentileschi, Stefano;Di Cianni, Federica;Urban, Maria Letizia;Chiara, Emanuele;Marinello, Diana;Del Bianco, Alessandra;Figus, Michele;Posarelli, Chiara;Fabiani, Claudia;Vagnani, Sabrina;Andreozzi, Gianni;Lorenzoni, Valentina;Turchetti, Giuseppe;Cauli, Alberto;Emmi, Lorenzo;Salvarani, Carlo;Della Casa Alberighi, Ornella;Bombardieri, Stefano;Mosca, Marta

2025-01-01

---

Abstract

Introduction: Evidence from randomised controlled trials on anti-tumour necrosis factor (TNF) agents in patients with Behçet's syndrome (BS) is low. Method: We conducted a phase 3, multicentre, prospective, randomised, active-controlled, parallel-group study to evaluate the efficacy and safety of either infliximab (IFX) or adalimumab (ADA) in patients with BS. Adults patients with BS presenting with active mucocutaneous manifestations, occurring while on therapy with either azathioprine or cyclosporine for at least 3 months prior to study entry, were eligible. Participants were randomly assigned (1:1) to receive IFX or ADA for 6 months. The primary study outcome was the time to response of manifestations over 6-month anti-TNF alpha agents' treatment. Results: 42 patients underwent screening visits, of whom 40 were randomly assigned to the IFX group (n=22) or to the ADA group (n=18). All patients at the time of randomisation had active mucocutaneous manifestations and a smaller proportion had concomitant vital organ involvement (ie, six and three patients with ocular and neurological involvement, respectively). A total of 14 (64%) responders in the IFX group and 17 (94%) in the ADA group were observed. Retention on treatment was 95% and 94% in the IFX and in the ADA group, respectively. Quality of life resulted to be significantly improved in both groups from baseline, as well as Behçet's Disease Current Activity Form assessment. We registered two adverse events (one serious) in the ADA group and three non-serious adverse events in the IFX group. Discussion: The overall results of this study confirm the effectiveness of both IFX and ADA in achieving remission in patients with BS affected by mucocutaneous involvement.